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Glucocorticosteroids (GCS) l have profound effects on both human and animal 
immune systems. These effects are generally suppressive in vitro as well as in 
vivo, with steroids acting at many levels in the immune response. Thus it was 
very surprising to discover that GCS can stimulate polyclonal production and 
secretion  of all  classes  of immunoglobulin  (Ig)  by  human  peripheral  blood 
mononuclear cells (PBMC) in vitro (1).  This activation results in an increase in 
immunoglobulin-secreting cells (IgSC) similar in  magnitude to that seen with 
pokeweed mitogen (PWM), although the peak response is seen at 7-10 d  after 
culture initiation, a few days later than with PWM. As with PWM, GCS stimu- 
lation is dependent on both T  cells and monocytes. The activation occurs within 
an extremely broad range of GCS concentrations (10  -4 M  to  10 -1° M) which 
includes the physiologic range for hydrocortisone (roughly 10  -6 M to  10  -7 M). 
Remarkably, this very large increase in IgSC develops with no detectable cellular 
proliferation. 
Several mechanisms of action for GCS in this system are possible. GCS have 
profound effects on T  cells and lymphokine production by monocytes and T 
cells (2-7);  so inactivation of suppressor  T  cells, induction of T  helper cells, 
inhibition of lymphokine production, or effects on the non-T cell population 
are all possibilities. In initial studies to determine the cellular target for GCS, T 
cells  and  non-T  cells  were  preincubated  with  and  without  GCS,  and  then 
recombined in various combinations of these populations.  No Ig was produced 
in any of these cultures. As a  different approach to this problem, supernatant 
fluids from cultures unstimulated or treated with a  variety of activators were 
tested for effects on GCS-induced Ig production by non T  cells. Unstimulated 
3-d cultures of PBMC  contain a  T  cell-replacing factor(s) that  enables a  T- 
depleted PBMC population to develop IgSC with the addition of GCS. Since T 
IAbbreviations used in  this paper: BCGF,  B cell  growth  factor;  Con  A,  concanavalin  A;  CyA, 
cyclosporin A; Dex, dexamethasone;  FCS, fetal calf serum; GCS, glucocorticosteroids;  Ig, immuno- 
globulin; IgSC,  immunoglobulin-secreting  cells; IL-I, interleukin 1;  IL-2,  interleukin 2;  PBMC, 
peripheral blood mononuclear cells; PHA, phytohemagglutinin;  PWM, pokeweed mitogen; RHPA, 
reverse  hemolytic  plaque assay; SEM, standard error of the mean; TRF-S, steroid-dependent T 
cell-replacing factor. 
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cells are never exposed to GCS in these experiments, neither suppressor T  cell 
inactivation,  inhibition  of T  cell  lymphokine  production,  nor  helper  T  cell 
induction is necessary for steroid-induced Ig production and secretion. There- 
fore,  the cellular target for GCS  in  the induction of IgSC  must reside  in  the 
non-T  cell  population  of PBMC,  and  the  T  cell  requirement  for  the  steroid 
response is mediated by a soluble factor produced by unstimulated PBMC. 
Materials and Methods 
Cell Preparations.  PBMC as well as T cells and non-T cells were prepared as previously 
described (1). 
Supernatant Preparations.  PBMC were cultured, in general, for 3 or 4 d in 5 ml starting 
with a cell concentration of 5 x  l0  s cells/ml in RPMI 1640 (Gibco Laboratories, Grand 
Island, NY) supplemented with 10% fetal calf serum (FCS, Reheis), L-glutamine (2 raM), 
and gentamicin (5 #g/ml) in 50-ml  flasks (25100;  Costar, Data Packaging, Cambridge, 
MA). Some cultures were stimulated with dexamethasone (Dex, Sigma Chemical Co., St. 
Louis, MO), phytohemagglutinin (PHA, Gibco),  pokeweed mitogen (PWM, Gibco),  or 
concanavalin A (Con A, Gibco).  Supernatants were harvested by pelleting the cells and 
filtering the decanted fluid through 0.45-#m Millipore filters. Supernatants were either 
used immediately or stored at 4°C. 
Preparation of Monocyte-depleted Populations.  A suspension of l0 s PBMC in 5 mi RPMI 
1640 with 20% FCS was put in a 250-ml flask (Costar, 3275) and 4 ml of Lymphocyte 
Separator Reagent (Technicon Instruments Corp., Tarrytown, NY) with 1 cm  3 of FCS 
was added. The suspension was incubated at 37°C in a humidified 5% CO2 atmosphere 
with the flask in a horizontal position for 90 rain. Nonadherent cells were decanted and 
then a  magnet was  used to  remove the iron  filings and  any residual iron-containing 
phagocytic cells from the suspension. The remaining lymphoid cells were subjected to a 
density gradient centrifugation on Ficoli-Hypaque (Bionetics  Laboratory Products, Ken- 
sington, MD). The interface cells contained <1% cells staining for nonspecific esterase 
(8). 
Lymphocyte Cultures.  PBMC and separated cell populations were cultured with Dex, 
PWM, and Epstein-Barr virus (EBV, supernatant of  cell line B95-8), as previously described 
(1). Cyclosporin A (CyA, Natural Products Branch, Division of Cancer Treatment, NCI, 
NIH, Bethesda, MD) was used at a concentration of 1 #g/ml. 
IgSC Assay.  At the end of the culture period (8-10 d in these experiments), a reverse 
hemolytic plaque assay (RHPA) as previously described (9) was used to detect IgSC. 
Results 
Preincubation of Separated Cell Populations with GCS 
To  try  to  determine  the  cellular  target  for  GCS  in  the  induction  of  Ig 
production, preincubation experiments were performed using PBMC separated 
into  T  cell  and  non-T  cell  populations  by  sheep  erythrocyte rosetting.  The 
separated populations were then cultured for 24-48 h in the presence or absence 
of GCS.  After the  preincubation  period,  cultures  were  washed extensively to 
remove the steroids. The various populations were then recombined and cultured 
with or without additional glucocorticoids. Cultures of either T  or non-T cells 
preincubated with 10 -6 M Dex but no additional GCS did not develop increased 
numbers  of IgSC  (geometric  mean  <300  IgSC/culture  in  four  experiments). 
Nonetheless, these cultures could still respond to stimulation by adding GCS to 
the  final culture  suspension  (in  two  experiments,  a  geometric  mean of 3,369 
IgSC/culture for 48 h GCS preincubated T  cells +  non-T cells, and 4784 IgSC/ 
culture for T  cells +  48 h GCS preincubated non-T cells). ORSON  ET  AL.  1475 
Comparison of Supernatants from Stimulated and Unstimulated Cultures  for T 
Cell-replacing Activity in Steroid-induced Ig Production 
Using another approach to define the cellular target for GCS, supernatants of 
PBMC stimulated in a variety of ways were tested for their ability to induce Ig 
production by T-depleted PBMC. As shown in Table I, only supernatants from 
cultures that  were unstimulated or treated with  GCS  contained significant T 
cell-replacing activity for steroid-induced Ig production in a non-T cell popu- 
lation. Treatment of supernatant cultures with various other stimulants (PWM, 
Con A,  PHA, and alloantigens) all  failed to result in culture fluids that could 
significantly replace T  cells. Supernatant fluids from cultures treated with GCS 
do contain this steroid-dependent T  cell-replacing activity (TRF-S), although at 
somewhat lower potency than those from untreated cultures. Further addition 
of GCS to supernatants of steroid-treated cultures is not necessary for TRF-S 
activity, presumably due to the persistence of sufficient GCS from the supernatant 
culture. TRF-S concentrations in the supernatants are low since the supernatants 
must be used at relatively high concentrations for steroid induction of IgSC in a 
T-depleted population.  Minimum final concentrations of supernatant are gen- 
erally in the range of 25%, although occasional preparations may have activity 
at 12.5% (data not shown). 
Cellular Requirements  for the Production of TRF-S 
Unseparated PBMC without added stimulants produce TRF-S when cultured 
in vitro for 3 or 4 d. Shorter or longer incubation times diminish the activity of 
the supernatant, although detectable activity may be present as early as 2 and as 
late as 6 d  (data not shown). Experiments to determine conditions for maximal 
TRF-S  production  revealed that  5  x  106  cells/ml in  5-ml  volumes was most 
efficient (geometric mean X  standard error of the mean in three experiments 
was 4,342 ~  1.24 IgSC/culture), while 2.5 x  106 cells/ml produced less TRF-S 
activity (2,103 --g  1.26) and 107 cells/ml produced no more (3,934 ~  1.42). 
TABLE  I 
Analysis of Various Culture Supernatants for T Cell-replacing  Factor 
(TRF-S) Activity 
Source of supernatant  t 
tested 
lgSC/Culture* (+x SEM*) 
+GCS I  -GCS 
None  406 (1.64)  <300 (-) 
Unstimulated  4,496 ( 1.48)  <300 (-) 
Dex  2,622 (1.24)  3,098 (1.24) 
PWM  <300 (-)  <300 (-) 
Con A  701 (1.73)  <300 (-) 
PHA  <300 (-)  <300 (-) 
MLR  694 (1.13)  <300 (-) 
* All cultures contained 5  x  l0 s non-T  cells in a volume of 1 ml. 
* Standard error of the geometric mean of three or more experiments. 
0 Suj~ernatants were harvested at 3  d  from 5-ml cultures containing 5  x 
10  ~ PBMC/ml with or without stimulants as indicated. Final supernatant 
concentration in the indicator cultures was 50%. 
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Cultures  of separated  cell  populations  revealed  that  TRF-S  production  is 
dependent on both T  celis and monocytes. As shown in  Fig.  1, T  cells alone, 
adherent cells alone, and T cells with B cells all fail to produce TRF-S-containing 
supernatants.  However, cultures of T  cells with adherent cells as well as  un- 
separated PBMC cultures produce TRF-S. Experiments using supernatants of T 
cell  cultures  combined  with  supernatants  of adherent  cell  cultures  failed  to 
induce an increase in  IgSC from non-T cells in the presence of GCS (data not 
shown). Thus, both T  cells and monocytes must be present in culture for TRF- 
S to be produced. Although B  cells have not rigorously been excluded from 
participation, the need for B cells in TRF-S production seems unlikely. 
Characteristics of TRF-S Action 
TRF-S replacement of T  cells in the steroid-induced IgSC response of non-T 
cell cultures shows a  time course similar to  that seen with  GCS  treatment of 
unseparated PBMC (1), showing a maximal response at 8-10 d (data not shown). 
To investigate the possibility that TRF-S might be acting on residual contami- 
nating T  cells in  the T-depleted population,  experiments using cyclosporin A 
(CyA) to block T  cell function were examined for steroid induction of IgSC with 
TRF-S. CyA strongly inhibits the response of PBMC to stimulation with GCS as 
well as  other T  cell-dependent activators,  such as  PWM.  Steroid-stimulated 
cultures of PBMC  treated with CyA developed few IgSC (geometric mean in 
three experiments was 475 ~  1.27 IgSC/culture), compared with controls (9,444 
-~  1.21).  However, when TRF-S-containing supernatants were added to other- 
wise identical cultures, a large increase in IgSC occurred (7,676 ~  1.21). Thus, 
it is unlikely that TRF-S acts on residual T  cells contaminating the T-depleted 
population. 
Although TRF-S replaces the requirement for T  cells in the steroid induction 
of IgSC, it does not replace the helper T  cells needed for Ig production induced 
by  another  polyclonal  activator,  PWM  (Fig.  2)  (10).  As  reported  by  other 
investigators, the T  cell-replacing factor for PWM is also different in its produc- 
20,OOG 
10,000 
~  3,000 
1,000 
_L300  ._ ~ 
Supernatant  PBMC  T Cells  T+ B  Adherent  Adherent 
Source  Cells  Cells  + T Cells 
FIGURE  l.  Both T  cells and monocytes must be present in culture for TRF-S to be produced. 
.5 x  105 T-depleted PBMC were cultured with  10  -6 M  Dex in a  volume of 1 ml. Supernatants 
were  harvested  from  unstimulated  cultures  of  various  cell  populations  and  used  at  .50% 
concentration  in  test  cultures.  Each  bar  represents  the  geometric  mean  of five  or  more 
experiments (+X standard error of the mean). ORSON  ET  AL.  1477 
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FIGURE 2.  TRF-S replaces the T  cell requirement for the GCS induced, but not the PWM- 
induced, IgSC  response. 5  x  105  T-depleted PBMC  were cultured  in  a  volume of 1  ml. 
Supernatant concentration was 50%.  Each bar represents the geometric mean of 10 experi- 
ments ( +x standard error of the mean). 
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FIGURE 3.  Monocytes are required for the expression of TRF-S activity. 5 x  105 T-depleted 
PBMC or 5 ×  105 B cells were cultured in a volume of 1 ml. Supernatant concentration was 
50%. Dex concentration was 10  -6 M, and EBV was used at a  10% final concentration. 
tion, requiring only T  cells,  which must be stimulated with PWM (11).  Since 
TRF-S can be produced in the absence of stimulation, requires GCS for the 
expression of its activity, and does not help B cells respond to PWM, TRF-S and 
the helper factor for PWM can be clearly distinguished functionally. 
Rigorous depletion of monocytes eliminates the capacity of lymphocytes to 
respond to GCS. This dependence on monocytes is also present in the steroid 
induction of IgSC from B cells using TRF-S. PBMC were depleted of monocytes 
by the adherence and iron carbonyl technique, and then subjected to separation 
of the T  and B cell populations by sheep erythrocyte rosetting. As shown in Fig. 
3, the monocyte-depleted B cell fraction responded appropriately to stimulation 1478  GLUCOCORTICOID-INDUCED IMMUNOGLOBULIN  PRODUCTION 
with the T  cell- and monocyte-independent activator EBV, but lost its respon- 
siveness to TRF-S with GCS. 
Physicochemical Characteristics of TRF-S 
TRF-S,  like  many  other  cytokines previously  described  (12-14),  contains 
protein essential for its activity. Supernatants with TRF-S activity were exposed 
to  trypsin  insolubilized  on  polyacrylamide beads,  for  1  h  at  37°C.  Treated 
supernatants lost all TRF-S activity (geometric mean for four experiments was 
<300 IgSC/culture), whereas supernatants not exposed to trypsin, but otherwise 
treated in the same fashion, retained TRF-S activity (2,099 ~  1.08 IgSC/culture). 
This  loss  of activity was not due to  toxicity or nonspecific suppression  of Ig 
production caused by the trypsin treatment, since treated supernatants had no 
suppressive effect on the B cell response to stimulation with EBV. 
Further characterization of this cytokine has been difficult due to instability 
of the factor activity. Among the conditions to which the activity of TRF-S is 
sensitive are heating to 56°C, freezing, lyophilization, exposure to pH <6 or >9, 
and storage at 4°C for >3 wk (data not shown). Dialysis of supernatants for 4 h 
with cellulose dialysis tubing having a molecular weight cutoff of 10,000 daltons 
has  no  effect on  TRF-S  activity  (geometric  mean  for  five  experiments  was 
2,329  --~  1.67  IgSC/culture,  with  controls  of  2,137  ~  1.33),  suggesting  a 
molecular weight of at  least  10,000  daltons.  Unfortunately, longer periods of 
exposure to  dialysis  tubing  result  in  complete loss  of activity even  when  no 
dialysate is used, presumably because of TRF-S binding to the dialysis membrane. 
Attempts to  purify activity by  running  supernatants  over a  Sephadex  G-100 
column have likewise been unsuccessful, possibly due to binding of TRF-S to the 
Sephadex,  dilution  of the  material  below  the  level of detection in  this  assay 
system, or separation of two or more components essential for TRF-S activity. 
Discussion 
GCS activity as an  in vitro polyclonal activator of Ig production presents a 
novel observation that clearly involves a different mechanism of steroid action 
than those previously recognized. Studies published by this laboratory presented 
preliminary  evidence  that  this  steroid  effect  was  not  through  inhibition  of 
suppressor T  cell function (1).  The current experiments conclusively eliminate 
that  mechanism  of action  since  T  cells  may  be  replaced  by  soluble  factors 
produced in the absence of GCS. Not only is steroid inhibition of suppressor T 
cells not required, but likewise neither helper T  cell induction nor inhibition of 
lymphokine production  by  T  cells  is  the  direct mechanism of glucocorticoid 
activity. The cellular target for GCS  must therefore reside in the non-T cell 
population of PBMC. 
TRF-S appears to be a unique cytokine that can be distinguished from those 
previously described by its production and activity characteristics. The primary 
differentiating  feature  of this  cytokine  is  in  the  GCS  requirement  for  the 
expression of its activity in the induction of IgSC. This activity as a maturation 
factor is similar to that of the helper factors described for PWM, alloantigens, 
or tetanus toxoid stimulation of human cells (11,  15-19).  However, TRF-S can 
be distinguished from these factors in  several ways. First, purified T  cells can ORSON ET  AL.  1479 
produce the other factors and do so only if stimulated by mitogens or antigens. 
TRF-S does not require such stimulation and can be obtained only from cultures 
in which T  cells and monocytes from the same donor are both present. Further- 
more, cultures stimulated with PWM or alloantigens do not contain significant 
amounts of TRF-S activity. Such supernatants could contain activity masked by 
other, suppressive factors, since supernatant  mixing experiments demonstrate 
suppression of the expected IgSC increase when such stimulated supernatants 
are added to cultures of non-T cells treated with TRF-S-containing supernatants 
and  GCS  (data  not  shown).  Secondly,  the  PWM-,  alloantigen-,  and  tetanus 
toxoid-induced helper factors require no further stimulation for Ig synthesis to 
occur, while TRF-S has no effect on Ig production without the addition of GCS. 
Furthermore,  the addition  of PWM  to  TRF-S-treated  cultures produces no 
increase  in  IgSC  from  T-depleted  PBMC.  The  addition  of  GCS  to  PWM 
supernatants likewise results in no increase of IgSC. Thus TRF-S and previously 
described maturation factors can be clearly differentiated. 
TRF-S also differs from other more completely characterized cytokines such 
as B cell growth factor (BCGF),  interleukin-1  (IL-1), and interleukin-2 (IL-2). 
BCGF differs in its production as well as in its activity (12, 20). BCGF is produced 
in mixed lymphocyte reactions, whereas alloantigenic stimulation does not induce 
TRF-S activity. The function of BCGF is also different in that it induces B cells 
to proliferate, but does not induce differentiation to IgSC (12,  20).  Likewise, 
both IL-1 and IL-2 can be produced from purified cell populations, monocytes, 
and T  cells, respectively, and require stimulation to trigger cytokine production. 
IL-1  has  many described functions, but  any direct effect on  B  cells remains 
controversial. Some experimental systems suggest that an IL-1  influence on B 
cells is required before the activity of a maturation factor to develop Ig produc- 
tion,  but  more  likely  the  increased  Ig  production  detected  is  due  to  IL-1 
enhancement of the helper function of residual contaminating T  cells in non-T 
cell populations (21). Certainly unstimulated cultures should produce very little 
IL-1 (14), and furthermore GCS inhibits IL-1 production by monocytes (4). Thus 
it is unlikely that IL-1  is a major participant in the GCS response. IL-2 activity 
seems more restricted to the maintenance of T  cell proliferation (22). There is 
very little  evidence of a  direct effect on  B  cells,  and  as with  IL-1,  GCS  are 
profound inhibitors of IL-2 production (2).  Screening experiments using crude 
preparations of IL-1 and IL-2 added to cultures of non-T cells stimulated with 
GCS did not result in stimulation of Ig production (data not shown). Thus neither 
BCGF,  IL-1,  nor  IL-2  production  or activity characteristics correspond with 
those described here for TRF-S. 
The physiologic implications of these observations for in vivo immune function 
are unknown. Glucocorticoids obviously have profound effects on diverse body 
tissues, but perhaps the most relevant known effect is the induction of maturation 
in  numerous immature tissues.  Fetal  lung, stomach, intestine, pancreas,  liver, 
brain,  skin,  and  retina  are  morphologically,  biochemically,  and  functionally 
induced to a more mature state under the influence of GCS (23). Likewise, GCS 
can advance the differentiation of prepartum breast tissue by inducing lacto- 
genesis (23). The quantity of GCS-induced Ig production by B cells is profound 
and since it occurs in vitro at physiologic concentrations, there must be regulatory 1480  GLUCOCORTICOID-INDUCED  1MMUNOGLOBULIN  PRODUCTION 
mechanisms in  vivo to prevent uncontrolled "spontaneous"  maturation  to  Ig- 
synthesizing cells. One mechanism could be the lack of proliferation associated 
with the steroid effect, which thus limits the production of a  particular immu- 
noglobulin by a cell beyond a certain level of differentiation to the period of Ig 
synthesis of that individual cell. Another possible mechanism in vivo is inhibition 
of the GCS effect by other factors. One such inhibitor currently being investi- 
gated by our laboratory is present in human serum, since cultures of PBMC from 
75% of normal donors are inhibited from developing steroid-induced IgSC by 
the addition of human serum. Although the true physiologic significance of the 
in vitro maturation of B cells induced by GCS remains unknown, the activity of 
glucocorticoids at physiologic concentrations and the preliminary evidence of 
regulatory  mechanisms suggest  that  steroids  may play  a  role  in  the  normal 
differentiation pathway of human B cells. 
Summary 
Glucocorticosteroids (GCS) added to otherwise unstimulated cultures of hu- 
man  peripheral  blood  mononuclear  cells  (PBMC)  induce  the  synthesis  and 
secretion of all  classes of immunoglobulin. The magnitude of this response is 
similar to  that  seen with other Polyclonal B  cell activators such as pokeweed 
mitogen (PWM), and like that of PWM, the steroid effect is dependent on both 
T cells and monocytes. To determine the cellular target for GCS in these cultures, 
separated populations of T cells and non-T cells were preincubated with steroids 
and then recombined. No immunoglobulin was produced in any of these prein- 
cubation experiments.  As a  different approach  to  this  question,  supernatants 
were collected from various cell populations following stimulation with PWM, 
concanavalin A (Con A), phytohemagglutinin (PHA), alloantigens, or GCS. These 
supernatants were tested for their effects on GCS-induced Ig production by B 
cells. Supernatants from 3-d cultures of unstimulated, as well as GCS-treated, 
PBMC contained a T  cell-replacing factor that permitted T-depleted PBMC to 
produce Ig upon steroid stimulation. This supernatant factor (TRF-S) could be 
produced in the absence of steroid stimulation, but  both  the factor and GCS 
were  necessary for  the  induction  of Ig  synthesis.  Production  of the  TRF-S 
required the presence of both T  cells and adherent cells in culture and was found 
in the highest concentrations at  3-4  d  of culture. Supernatants from cultures 
stimulated with PWM, PHA, Con A, and alloantigens did not contain detectable 
TRF-S  activity, and  TRF-S  was  unable  to  replace  helper  T  cells  for  PWM- 
induced Ig production. TRF-S required the presence of adherent cells in the T 
cell-depleted responder population  for its action.  Further, it was effective in 
inducing Ig production along with GCS in the presence of a sufficient concen- 
tration of cyclosporin A to block all T  cell helper activity for primary responses 
of PBMC to PWM or GCS. TRF-S was inactivated by trypsin treatment, heating 
to 56°C,  freezing, lyophilization, and storage at 4°C for >3 wk.  Its molecular 
weight is probably  10,000  daltons or more, since TRF-S activity is not rapidly 
dialyzable.  These  experiments  indicate  that  GCS-induced  Ig  production  by 
human B cells does not require the presence of intact T  cells in the cultures and 
therefore the steroids are not exerting their influence directly on T  suppressor 
or T  helper cells.  Furthermore, they demonstrate a  previously unrecognized ORSON  ET  AL.  1481 
cytokine that induces the differentiation of human B cells to  Ig production in 
the presence of GCS. 
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